Sawai Group Holdings Revises Financial Results Due to Litigation Costs

The latest update is out from SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ).

Sawai Group Holdings Co., Ltd. announced a correction to its consolidated financial results for the fiscal year ended March 31, 2025, due to a provision for loss on litigation amounting to JPY 16,757 million. This adjustment significantly impacted the company’s financial statements, reflecting a decrease in operating profit and profit before tax, highlighting challenges in their financial performance and potential implications for stakeholders.

The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.

More about SAWAI GROUP HOLDINGS Co., Ltd.

Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, focusing primarily on the production and distribution of generic drugs. The company is listed on the Tokyo Stock Exchange and aims to provide affordable medication solutions, contributing to the healthcare sector by enhancing access to essential medicines.

Average Trading Volume: 613,272

Technical Sentiment Signal: Sell

Current Market Cap: Yen177.6B

See more insights into 4887 stock on TipRanks’ Stock Analysis page.